Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Inhibition of enterovirus 71 infection by antisense octaguanidinium dendrimer-conjugated morpholino oligomers

Chee Wah Tan\textsuperscript{a}, Yoke Fun Chan\textsuperscript{a,b}, Yi Wan Quah\textsuperscript{c}, Chit Laa Poh\textsuperscript{c,*}

\textsuperscript{a}Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
\textsuperscript{b}Tropical Infectious Disease Research and Education Center, University of Malaya, 50603 Kuala Lumpur, Malaysia
\textsuperscript{c}Faculty of Science and Technology, Sunway University, 46150 Petaling Jaya, Selangor, Malaysia

Abstract

Enterovirus 71 (EV-71) infections are generally manifested as mild hand, foot and mouth disease, but have been reported to cause severe neurological complications with high mortality rates. Treatment options remain limited due to the lack of antivirals. Octaguanidinium-conjugated morpholino oligomers (vivo-MOs) are single-stranded DNA-like antisense agents that can readily penetrate cells and reduce gene expression by steric blocking of complementary RNA sequences. In this study, inhibitory effects of three vivo-MOs that are complementary to the EV-71 internal ribosome entry site (IRES) and the RNA-dependent RNA polymerase (RdRP) were tested in RD cells. Vivo-MO-1 and vivo-MO-2 targeting the EV-71 IRES showed significant viral plaque reductions of 2.5 and 3.5 log\textsubscript{10} PFU/ml, respectively. Both vivo-MOs reduced viral RNA copies and viral capsid expression in RD cells in a dose-dependent manner. In contrast, vivo-MO-3 targeting the EV-71 RdRP exhibited less antiviral activity. Both vivo-MO-1 and 2 remained active when administered either 4 h before or within 6 h after EV-71 infection. Vivo-MO-2 exhibited antiviral activities against poliovirus (PV) and coxsackievirus A16 but vivo-MO-1 showed no antiviral activities against PV. Both the IRES-targeting vivo-MO-1 and vivo-MO-2 inhibit EV-71 RNA translation. Resistant mutants arose after serial passages in the presence of vivo-MO-1, but none were isolated against vivo-MO-2. A single T to C substitution at nucleotide position 533 was sufficient to confer resistance to vivo-MO-1. Our findings suggest that IRES-targeting vivo-MOs are good antiviral candidates for treating early EV-71 infection, and vivo-MO-2 is a more favorable candidate with broader antiviral spectrum against enteroviruses and are refractory to antiviral resistance.

1. Introduction

Enterovirus 71 (EV-71) is a single-strand, positive-sense RNA virus. EV-71 usually cause mild hand, foot and mouth disease (HFMD) characterized by fever with papulovesicular rash on the palms and soles (Ooi et al., 2010). In recent years, EV-71 infections were also associated with neurological complications with high mortalities among infants and young children < 6 years old (Solomon et al., 2010). To date, no effective antiviral agent is available for clinical use (Shang et al., 2013b; Tan et al., 2014). Thus, there is an urgent need to develop effective antiviral agents to treat EV-71 infection.

Considering the morbidity caused by EV-71, new approaches to the development of therapeutics are needed. A number of promising RNA-based therapeutics designed to inhibit EV-71 infections have shown promising results, including siRNA and shRNA (Deng et al., 2012; Sim et al., 2005; Tan et al., 2007a,b; Wu et al., 2009). However, the limitations of RNA-based therapeutics are short half-life and it required a delivery agent which might be toxic to the host. Therefore, nucleic acid-based therapeutics should be designed to possess favorable pharmacological properties such as in vivo stability and low toxicity.

A phosphorodiamidate morpholino oligomer (PMO) is a single-stranded DNA-like compound that has the ability to bind to the mRNA and inhibit gene expression by steric blockage of complementary RNA. PMOs are highly nuclease-resistant and do not require the RNase H or other catalytic proteins for their activity (Kole et al., 2012; Summerton, 1999). PMOs have been conjugated with various cell-penetrating compounds such as cell-penetrating peptides and octaguanidinium dendrimers which are able to enhance their uptake by cells (Moulton and Jiang, 2009). Peptide conjugated-PMOs (PPOMO) have been demonstrated to inhibit various viral infections, including Ebola virus (Warfield et al., 2006), West Nile virus (Deas et al., 2005), dengue virus (Kinney et al., 2005), sindbis virus (Paessler et al., 2008), coronavirus (Neuman et al., 2012; Sim et al., 2005; Tan et al., 2007a,b; Wu et al., 2009).
et al., 2004), herpes simplex virus 1 (Moerdyk-Schauwecker et al., 2009), porcine reproductive and respiratory syndrome virus (Opriessnig et al., 2011; Patel et al., 2008), foot-and-mouth disease virus (Vagnozzi et al., 2007), poliovirus, rhinovirus (Stone et al., 2008), and coxsackievirus B3 (Yuan et al., 2006).

In this study, three octaguanidinium dendrimer conjugated-morpholino oligomers (vivo-MOs) targeting the EV-71 internal ribosome entry site (IRES) core sequence and the RNA-dependent RNA polymerase (RdRP) were tested for their inhibitory effects against EV-71. We demonstrated that the two vivo-MOs targeting the IRES core sequence showed significant inhibition of EV-71 infection.

2. Materials and methods

2.1. Cells and viruses

Rhabdomyosarcoma (RD, ATCC) cells were grown in Dulbecco's modified Eagle’s medium (DMEM, Hyclone) supplemented with 10% fetal bovine serum (FBS). EV-71 strains 41 (GenBank accession number: AF316321), BrCr (GenBank accession number: AB204852) and UH1/97 (GenBank accession number: AM396587); coxsackievirus A16 (CV-A16), PV and chikungunya virus (CHIKV) strain MY/08/065 (GenBank accession number: FN295485) were propagated in RD cells.

2.2. Vivo-MOs

All vivo-MOs were synthesized by Gene Tools LLC (USA). The 23-mer vivo-MOs were designed to be complementary to the EV-71 (strain 41) IRES stem-loop V-VI and the RdRP gene (Table 1, Fig. 1). All the vivo-MOs were dissolved in phosphate buffer saline (PBS) at concentration of 0.5 mM. The cytotoxicity of the vivo-MOs were evaluated using Cell Titer 96 AQueous cell proliferation reagent (Promega) according to the manufacturer's instructions.

2.3. In vitro inhibitory effects of vivo-MOs in RD cells

RD cells were seeded at 1.5 × 10⁴ cells or 1.5 × 10⁵ cells within each well of a 96-well plate or 24-well plate, respectively and incubated overnight at 37 °C in 5% CO₂. After overnight incubation, the growth medium was removed and replaced with EV-71 inoculum with a multiplicity of infection (MOI) of 0.1 (PFU per cell) and incubated at 37 °C for 1 h. After incubation, the inoculum was removed and replenished with maintenance medium (DMEM with 2% FBS) with or without vivo-MOs. The inhibitory effects of the vivo-MOs were evaluated by plaque assay, TaqMan real-time RT-PCR and western blot analysis 24 h post-infection (hpi) as previously described (Tan et al., 2012, 2013). The western blot signal was enhanced using SuperSignal® western blot enhancer (Pierce Biotechnology).

2.4. Time of addition assay

Vivo-MOs were added to RD cells at various time points relative to viral inoculation. RD cells were pre-incubated with vivo-MOs at final concentration of 5 µM for 4 h before EV-71 inoculation at a MOI of 0.1. In concurrent studies, both vivo-MOs and EV-71 were added into RD cells for 1 h followed by replacement of medium without vivo-MO. For post-infection studies, RD cells were infected with EV-71 for 1, 2, 4 and 6 h before vivo-MOs were applied. The viral titers for each experiment were quantitated 24 hpi by plaque assays.

2.5. In vitro inhibitory effects of vivo-MOs against various enteroviruses

To evaluate the efficacy of vivo-MOs against different enteroviruses including CV-A16 and PV, RD cells were pre-incubated with vivo-MOs at the final concentration of 5 µM for 4 h before viral

---

The table below shows the sequence of the 23-mer vivo-MOs and target locations in EV-71 RNA.

**Table 1** Sequence of the 23-mer vivo-MOs and target locations in EV-71 RNA.

| Vivo-MOs | Sequence (5'–3') | Target location in EV-71 RNA (nucleotide position) |
|----------|-----------------|-----------------------------------------------|
| 1        | CAGAGTTGCCCATTCAGCACAC | IRES core (512–534) |
| 2        | GAAACACGGACACCCAAAGTAGT | IRES core (546–568) |
| 3        | AAACAATTCGAGCCAATTTCTTC | 3D Pol gene (7303–7325) |
| Control  | CCTACTCCATCGTTCAGCTCTGA | – |

---

**Fig. 1.** Schematic illustration of the EV-71 genomic structure. Three genomic vivo-MOs target sequences (5' to 3') are indicated as (1)-(3) within the proposed secondary structures of the IRES region and the RdRP gene of EV-71 RNA. The sequences of these three targeted regions were aligned across all EV-71 genotypes, CV-A16 and PV.
inoculation at a MOI of 0.1 for 1 h at 37 °C. The viral titers were determined 24 hpi by plaque assay. CHIKV was used as a negative control virus in this experiment.

2.6. Construction of EV-71 infectious cDNA clones

EV-71 strain 41 infectious clone was constructed using the full-length genome PCR approach according to Yeh et al. (2011) with modifications. The primers involved in the infectious clone constructions were listed in Table S1. Full-length genome RT-PCR was performed with Superscript III reverse transcriptase (Invitrogen) and iProof High-Fidelity polymerase (Bio-Rad) using pTSO/EgRI-R and pSP6/EV71-F primers. EV-71 expressing enhanced green fluorescence protein (EGFP) was constructed by overlapping extension PCR strategy using Q5 High-Fidelity polymerase (NEB). The EGFP gene was fused into the EV-71 genome between the 5' UTR and VP4 gene followed by the 2A cleavage site (-AI/TTL-) as previously described (Shang et al., 2013a). The full-length PCR product was then cloned into pCR-XL-TOPO (Invitrogen). 

2.7. Cell free translation inhibition assay

Cell free translation assay was performed with 1 μg of in vitro transcribed RNA using 1-step human coupled IVT kit (Pierce Biotechnology) either in the presence or absence of vivo-MOs according to the manufacturer's instructions. An aliquot of 20 μl of in vitro translated sample was subjected to SDS–PAGE and western blot analysis as described previously. The immunoblot was developed with Clarity™ Western ECL substrate (Bio-Rad) and detected by chemiluminescence.

2.8. EV-71–EGFP inhibition assay

RD cells in a 96-well plate were infected with EV-71–EGFP for an hour at 37 °C. After incubation, the inoculum was removed and replaced with maintenance medium containing 2.5 μM of vivo-MOs. The EGFP expression was observed at 6 hpi using fluorescence microscopy.

2.9. Generation of vivo-MOs resistant viruses

EV-71 was passaged in RD cells with increasing concentrations of either vivo-MO-1 or vivo-MO-2. For the first passage, RD cells were infected with EV-71 at a MOI of 0.1 for 1 h at 37 °C and the inoculum was removed and replaced with maintenance medium containing 1 μM of vivo-MO-1 or vivo-MO-2. Each selection was passaged by adding 100 μl of the supernatant into new RD cells. Viruses were passaged once at each of the concentrations ranging from 1 μM to 4 μM, followed by passing four times at 5 μM. To identify the mutation(s) which conferred resistance to vivo-MOs, viral RNA of an individual plaque population was amplified and subjected to DNA sequencing.

2.10. Reverse genetic analysis of vivo-MO resistant viruses

Point mutations were incorporated into the EV-71 infectious clone by using QuickChange Lightning site-directed mutagenesis kit (Agilent Technologies) according to the manufacturer's instructions. Four mutants were constructed with different nucleotide substitutions at the vivo-MO-1 targeted region (Table 2). The degree of resistance was evaluated using inhibitory assay as described in Section 2.3.

| Table 2 | Sequence of vivo-MO-1 and the in vitro transcribed infectious RNA with target sequences. |
|---------|------------------------------------------------------------------------------------------|
| Target  | Sequences |
| Vivo-MO-1 | 3’-CAGAGTTGCCATTACGACACAC-3’ |
| MO-1-WT | 5’-GTGTGTCTGAATGGGCAACTCTG-3’ |
| MO-1-mutant-1 | 5’-GTGTGTCTGAATGGGCAACTCCG-3’ |
| MO-1-mutant-2 | 5’-GTGTGTCTGAAGGGCAACTCTG-3’ |
| MO-1-mutant-3 | 5’-GTGTGTCTGAAGGGCAACTCTG-3’ |
| MO-1-mutant-4 | 5’-GTGTGTCTGAAGGGTAACTCTG-3’ |
| Mismatch(es) | – |
| MO-1-WT | 0 |
| MO-1-mutant-1 | 1 |
| MO-1-mutant-2 | 1 |
| MO-1-mutant-3 | 2 |
| MO-1-mutant-4 | 3 |

2.11. Statistical analysis

The data presented are the means ± standard deviations (SD) obtained from at least two independent biological replicates. Error bars represent the SD. Statistical significance was calculated using the Mann–Whitney test. A P value of <0.05 was considered statistically significant.

3. Result

3.1. Vivo-MOs complementary to EV-71 IRES stem-loop structures exhibited significant inhibitory activities

To evaluate the effects of vivo-MOs on EV-71 infectivity in RD cells, RD cells were treated with vivo-MOs an hour after infection. As shown in Fig. 2, both vivo-MOs targeting the EV-71 IRES stem-loop region exhibited significant antiviral activity against EV-71 infection with reduction of virus-induced CPE (Fig. 2A), plaque formation (Fig. 2B), RNA (Fig. 2C) and capsid expression (Fig. 2D) in a dose-dependent manner. The vivo-MO-1 and vivo-MO-2 significantly reduced EV-71 plaque formation by up to 2.7 and 3.5 log10 PFU/ml at 10 μM, respectively. Significant inhibition was observed at concentrations higher than 1 μM. The IC50 values of vivo-MO-1 and vivo-MO-2 were 1.5 μM and 1.2 μM, respectively. However, vivo-MO-3 exhibited less inhibitory effect against EV-71 infection in RD cells with a plaque reduction of only 1.2 log10 PFU/ml (Fig. 2B). The vivo-MO-C which has no homologous sequence to the EV-71 genome has no inhibitory effects at all against all EV-71 strains tested. None of the vivo-MOs caused more than 20% reduction of cell viability at concentrations less than 5 μM as measured by the MTS assay (Fig. 3).

3.2. Vivo-MOs blocked EV-71 infections at multiple time points

To further characterize the efficacy of vivo-MOs at multiple time points relative to EV-71 infection, vivo-MOs were applied for 4 h before, or 1, 2, 4, or 6 h after EV-71 infection. Both vivo-MO-1 and vivo-MO-2 remained effective when administered before or after EV-71 infection. However, the efficacies were reduced when treatments were delayed. When vivo-MOs and EV-71 were added together into the RD cells for 1 h, the inhibitory effect was reduced, which could have resulted from the incomplete uptake of the vivo-MOs by the cells. Nonetheless, the antiviral effects were retained for both IRES-targeting vivo-MOs even when administered 6 hpi, with 92.8% plaque inhibition. Vivo-MO-3 had no observable inhibitory effects on EV-71 infection when administered 4 h before infection and 2, 4, or 6 hpi (Fig. 4A).

3.3. Vivo-MO-2 exhibited broad-spectrum antiviral activities against various enteroviruses

Next, we investigate whether any of the vivo-MOs could inhibit different EV-71 strains as well as other picornaviruses. We evaluated each of the vivo-MOs against two other EV-71 strains (BrCr
and UH1/97), PV, CV-A16 and CHIKV as the control virus. The vivo-MO-2 which targets the highly conserved region of the IRES stem-loop structure exhibited significant inhibitory activity against EV-71 strains BrCr and UH1/97, PV and CV-A16 with viral plaque reduction ranging from 1.8 to 3.1 log$_{10}$ PFU/ml (Fig. 4B). However, vivo-MO-1 only exhibited antiviral activities against EV-71 strains BrCr and UH1/97, CV-A16, but not against PV (Fig. 4B). EV-71 strain BrCr which has a single nucleotide mismatch in the middle of the vivo-MO-1 targeted site (Fig. 1) remained sensitive to the vivo-MO-1 treatment. The efficacy of vivo-MO-1 against CV-A16 (0.95 log$_{10}$ PFU/ml reduction) was significantly lower when compared to EV-71 (1.86 log$_{10}$ PFU/ml reduction). This could be due to three nucleotide mismatches with the vivo-MO-1. PV with five nucleotide mismatches was completely resistant to the inhibitory effect of vivo-MO-1. All the vivo-MOs did not show any inhibition of CHIKV infection.

3.4. IRES-targeting vivo-MOs blocked EV-71 translation

To investigate the mechanism of action of the antiviral vivo-MOs, cell-free translation analysis was used. As depicted in Fig. 5A, the presence of either vivo-MO-1 or vivo-MO-2 significantly blocked the IRES-dependent translation when compared to the control. Vivo-MO-3 exhibits reduced efficacies as compared to IRES-targeting vivo-MOs. In the EV-71–EGFP inhibition assay, the presence of the vivo-MO-1 or vivo-MO-2 greatly reduced EGFP expression in RD cells 6 hpi with EV-71–EGFP (Fig. 5B).

3.5. Tolerance of vivo-MO-1 to mismatches within the target RNA

We explored whether EV-71 could become resistant to vivo-MO treatments. EV-71 was serially passaged in the presence of increasing concentrations of either vivo-MO-1 or vivo-MO-2. Interestingly, only EV-71 mutants resistant to vivo-MO-1 were isolated after eight passages. We failed to isolate EV-71 mutants that were resistant to vivo-MO-2. To investigate the determinant(s) of resistance, viral RNA was isolated from the resistant population and was sequenced. A single point mutation from T to C at position 533 was sufficient to confer resistance to vivo-MO-1 (Fig. 6A). To characterize the loss of inhibitory activity by vivo-MO-1, we constructed EV-71 mutants carrying different mismatches at the vivo-MO-1 target site (Table 2), and the inhibitory effects of vivo-MO-1 against each of the mutants
were evaluated. The mismatched RNA target sequences were designed to reflect the most likely natural variations that would arise in the EV-71 sequence. As shown in Fig. 6B, the EV-71 MO-1-mutant-1, which carried a single point mutation at position 533 (T to C substitution), required higher vivo-MO-1 concentrations to achieve a similar inhibitory effect when compared to the wild type. The EV-71 MO-1-mutant-2 with a single point mutation in the middle of the targeted sequence (a T to C substitution at position 523) remained sensitive to vivo-MO-1, but vivo-MO-1 had reduced inhibitory efficacy when compared with the wild type. Increasing the number of mutations on the targeted sequence significantly reduced the inhibitory efficacy of vivo-MO-1. The viral plaque inhibition at 2 μM of vivo-MO-1 against EV-71 MO-1-WT was 98.9% ± 0.1, and reduced to 89.6% ± 3.4 for the MO-1-mutant-1 that carried a point mutation at the 3’ end of the target sequence. The viral plaque inhibition by vivo-MO-1 reduced to 78.0% when the number of nucleotide mismatches increased to three.

4. Discussion

To date, there is no FDA approved vaccine available to prevent infection and treatment options remain limited due to a lack of effective antivirals (Chong et al., 2012; Shang et al., 2013b; Tan and Chan, 2013). Highly negatively-charged compounds like suramin or its analog, NF449 that disrupt the virus-host receptor interactions are ineffective when EV-71 mutants acquire Glu98Gln and Lys244Arg substitutions in the VP1 capsid protein (Arita et al., 2008; Tan et al., 2013). A single point mutation, Val192Met in
the VP1, is sufficient to confer resistance to the capsid binder BPROZ-194 (Shih et al., 2004). Therefore, there is an urgent need to develop effective antiviral agents to treat patients with severe EV-71 infection.

The use of antisense mechanisms to inhibit pathogen replication has been under investigation and has shown promising results. Foniviren, a 21-mer phosphorothioate oligonucleotide antisense agent used for intravitreal treatment of cytomegalovirus retinitis, is the only antisense agent that has been approved by the FDA to date (de Smet et al., 1999). There are advantages of vivo-MOs over RNA-based antisense oligomers as they are, nuclease-resistant and readily penetrate the cells (Kole et al., 2012; Moulton and Jang, 2009). These have an advantage over peptide-based cell penetrating molecules, which are susceptible to protease degradation that can impact the effectiveness of PPMOs (Youngblood et al., 2007).

Amongst the three vivo-MOs being examined, the two vivo-MOs targeting the EV-71 IRES stem-loop region exhibited significant antiviral activity. The vivo-MOs blocked EV-71 viral RNA translation in a cell-free inhibition assay, as well as in a cell-based EGFP reporter inhibition assay. Previous studies have also reported that only PMOs targeting the positive strand IRES regions or the AUG start codon sites were effective when compared to PMOs targeting other regions of the viral RNA (Stone et al., 2008; Vagnozzi et al., 2007; Yuan et al., 2006). The PMO may bind with the complimentary viral RNA and disrupt the integrity of the IRES stem-loop secondary or tertiary structures, hence arresting IRES-dependent translation (Kole et al., 2012; Warren et al., 2012). The PMOs are likely to block 40S ribosomal subunit binding the viral RNA in the vicinity of the stem-loop V in the picornaviral type I IRES (Belsham, 2009). Furthermore, it has been suggested that the IRES stem-loop V-VI of EV-71 interacts with IRES-specific trans-acting factors such as FUSE-binding protein and heterogeneous nuclear ribonucleoprotein Al (Lin et al., 2009a,b; Shih et al., 2011). Unlike synthetic double-stranded siRNA which involve cleavage of mRNA, PMOs are translation-suppressing oligonucleotides which do not lead to RNA degradation (Kole et al., 2012; Warren et al., 2012). This could explain why siRNA targeting the similar viral sequences as vivo-MO-3 was effective, but not acting as a translation suppression oligonucleotide which down-regulates gene expression via steric blockage. IRES-targeting vivo-MO-2 exhibited broad-spectrum activities against multiple enteroviruses, but with different antiviral efficacies. This could have resulted from the IRES stem-loop structure differences between enteroviruses which affect the accessibility of the vivo-MOs to the targeted sites (Dias and Stein, 2002).

In this study, an EV-71 mutant that was resistant to vivo-MO-1 carried a single substitution of T to C at position 533. We failed to isolate any EV-71 resistant to vivo-MO-2 even after eight passages in vitro, implying that the vivo-MO-2 targeted region is intolerant to mutation in nature. Our mutagenesis studies further confirm that the position of mutation and the number of mutations affect the antiviral efficacies in RD cells. A single mismatch present in the middle of the targeted sequence (T to C substitution at position 523) was more tolerable than a mutation appearing at the end of the targeted site (T to C substitution at position 533). These findings correlated well with previous findings that PV, FMDV and WNV that showed resistance to PPMO also carry a single point mutation at the end of the PPMO-targeted sequence (Stone et al., 2008; Vagnozzi et al., 2007; Zhang et al., 2008). A similar observation has been made for influenza virus as the degree of inhibition was associated with the number of mismatches (Ge et al., 2006).

5. Conclusion

In summary, we have established two critical locations that are involved in viral translation initiation in the EV-71 genome as targets for vivo-MO antiviral intervention. The vivo-MOs worked well with low micromolar concentrations to inhibit EV-71 infection and showed little cytotoxicity in RD cells. The potent inhibition of several entero viruses by vivo-MO-2 raises the possibility that it could be developed as a broad-spectrum antiviral agent. Furthermore, the degree of tolerance of mismatches by vivo-MOs suggests a favorable characteristic for their use as a potential antiviral agent.

Acknowledgements

This work was supported by a Ministry of Education E-Science Fund (02-02-16-SF0022) and Sunway University Research Grant (INT-FST-BIOS-0312-02) awarded to CLP, and a University Malaya High Impact Research grant (UM.C/625/1/HIR/ MOHE/ MED/41), Postgraduate research Grant (PV013-2012A) and Exploratory Research Grant Scheme (ER017-2013A) awarded to YFC.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.antiviral.2014.04.004.
